Semaglutide (rys) (Ozempic) is a glucagon-like peptide-1 (GLP‑1) analogue that binds to and activates the GLP‑1 receptor, the target for native GLP‑1. GLP‑1 is a physiological hormone that has multiple actions in glucose and appetite regulation, and in the cardiovascular system. The glucose and appetite effects are specifically mediated via GLP‑1 receptors in the pancreas and the brain. GLP‑1 receptors are also expressed in the heart, vasculature and immune system and kidney from where it may mediate cardiovascular and microvascular effects. Ozempic is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise: as monotherapy when metformin is not tolerated or contraindicated; or in addition to other medicinal products for the treatment of type 2 diabetes. Ozempic solution for injection contains semaglutide (rys) 1.34 mg/mL and is available in a pack size of 1 prefilled pen containing 1.5 or 3 mL.
New Indications
Teduglutide (Revestive) is now indicated for the treatment of paediatric patients 2 years of age and above with short bowel syndrome who are dependent on parenteral support.
Ustekinumab (Stelara)is now indicated for the treatment of adult patients with moderately to severely active ulcerative colitis.
This list is a summary of only some of the changes that have occurred over the last month.
Before prescribing, always refer to the full product information.
To contact MIMS editorial please email editorial@mims.com.au. To enquire about purchasing a product please contact MIMS Customer service on 1800 800 629 or email subscriptions@mims.com.au. For more information about MIMS, please see www.mims.com.au.
